Ideaya Biosciences Inc - Enters Clinical Collaboration Agreement With Astrazeneca On April 8, 2026 - SEC Filing

Reuters04-09
April 9 (Reuters) - IDEAYA Biosciences Inc ::
*IDEAYA BIOSCIENCES INC - ENTERS CLINICAL COLLABORATION AGREEMENT WITH ASTRAZENECA ON APRIL 8, 2026 - SEC FILING
*IDEAYA BIOSCIENCES INC - AGREEMENT TO EVALUATE IDE849 WITH IMFINZI IN EXTENSIVE-STAGE SMALL CELL LUNG CANCER - SEC FILING
*IDEAYA BIOSCIENCES INC - CO TO SPONSOR STUDY; ASTRAZENECA TO SUPPLY IMFINZI - SEC FILING
*IDEAYA BIOSCIENCES INC - ADVANCING GLOBAL PHASE 1 TRIAL FOR IDE849 IN DLL3 UPREGULATED SOLID TUMORS - SEC FILING
*Further company coverage: IDYA.O
* ((Reuters.Briefs@thomsonreuters.com;))

((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))
Source Date/Time = 09-APR-202610:13:15 GMT

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment